MedWatch

Analyst: This is Novo’s challenge on the obesity market

According to pharmaceutical analyst, Søren Løntoft Hansen, it is not the pending cancer case which is the biggest challenge for the entry of Novo’s diabetes drug Victoza on the obesity market. Meanwhile, he raises his peak sales estimate for the drug considerably.

Foto: colourbox

At a hearing in the U.S. last week, Novo Nordisk presented their side of the matter in a pending case about the potential effect of GLP-1 analogues on the development of pancreatitis and pancreatic cancer. One of the drugs being targeted in the case is the company’s blockbuster Victoza.

And the Danish company is currently preparing to launch the very same drug as a candidate for treating obesity.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier